Value through Innovation12 February 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Boehringer Ingelheim and researchers at The University of Michigan collaborate to study mechanisms of diabetic nephropathy in Pima Indians


Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions


FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD


Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment


Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT 2011 evidence based guidelines for treatment of idiopathic pulmonary fibrosis (IPF), suggesting nintedanib* for the treatment of IPF.


New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy1,2,3


New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups


Data Comparison shows onset of action of oral hyoscine butylbromide already as early as 15 minutes


Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate


Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung


First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation


2014: Boehringer Ingelheim positioned for future growth with product launches


New international survey of lung cancer oncologists highlights underutilization of personalized treatments

- For media outside the US, the UK and Canada only

Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders


Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union

- For media outside the US, the UK and Canada only

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study


- For Non-UK / Non-Canadian Media only

Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment

- For Non-US/Non-UK/Non-Canadian Media

EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe